SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):111P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Chong, A.
Right arrow Articles by Bom, H.-S.
PubMed
Right arrow Articles by Chong, A.
Right arrow Articles by Bom, H.-S.

Oncology-Clinical Diagnosis: Solid Tumors

Gynecological Cancers

Clinical impact of the FDG-PET in restaging of cervical cancer patients with increased tumor marker

Ari Chong1, Shin Young Jeong1, Seong-Young Kwon1, Young-Soon Seo1, Jung-Min Ha1, Jung-Joon Min1, Ho-Chun Song1, Ho-Sun Choi2 and Hee-Seung Bom1

1 Nuclear Medicine; 2 Obstetrics and Gynecology, Chonnam National University Hospital, Gwangu-ju, South Korea

442

Objectives: Clinical decision is acquired when tumor markers elevate in follow-up of treated cervical cancer if there is not any other evidence of recurrence or metastasis. In this study, we investigated the diagnostic value of PET/CT in these cases, determined by clinical follow-up of more than a year.

Methods: Cases enrolled were 30 cases of PET/CT which were for the restaging of cervical cancer due to increased tumor marker. Non of them showed clinical evidence of recurrence or metastasis. The average time interval from last treatment to PET/CT is 82 months. We investigated abnormal PET/CT findings which suggested recurrence or metastasis by retrograde study with pathologic confirmation or clinical follow-up. We also follow-up the cases with normal PET/CT results to investigate the rate of true negatives. The average follow-up interval after PET/CT is 14.27 months.

Results: 46.6% (14 cases) of them were supposed to have recurrent or metastastic lesions in PET/CT. 5 of them have been confirmed by biopsy. In other 7 cases, the recurrent malignancy were strongly suggested clinically or other imaging mordality and they started therapy. So overall 12 cases are true positives. 53.3% (16 cases) of them did not show any evidence of recurrence or metastasis in PET/CT. Among them, 15 cases have not shown any evidence of recurrence or metastasis during follow-up (16.67 months). There are 2 false-positive cases and only 1 false-negative case. So the overall sensitivity is 92.3% and the specificity is 88.2%.

Conclusions: The PET/CT can detect and rule out recurrence or metastasis in restaging of cervical cancer with increased tumor marker, when there is not any other evidence of recurrace or metastasis.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Chong, A.
Right arrow Articles by Bom, H.-S.
PubMed
Right arrow Articles by Chong, A.
Right arrow Articles by Bom, H.-S.